Axsome Therapeutics, Inc. reports news on its biopharmaceutical business focused on central nervous system disorders, including marketed medicines and late-stage neuroscience programs. Company updates commonly cover FDA actions, product revenue for AUVELITY, SUNOSI and SYMBRAVO, business results, investor presentations, and development activity in neurological and psychiatric conditions.
Recurring topics include AUVELITY for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease, SUNOSI for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, migraine treatment commercialization, and pipeline work involving solriamfetol, AXS-12 and PDE10A inhibitor programs.
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company specializing in therapies for CNS disorders, announced participation in two investor conferences. These events include the William Blair 44th Annual Growth Stock Conference on June 5 in Chicago, where CEO Herriot Tabuteau, MD, will present a corporate overview, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12 in Miami Beach, where Axsome leadership will conduct investor meetings. A live webcast of the William Blair presentation will be available on the company's website.
On May 29, 2024, Axsome Therapeutics (NASDAQ: AXSM) announced significant findings on solriamfetol at the SLEEP 2024 conference, held from June 1-5, 2024, in Houston, Texas. The presentations highlighted solriamfetol's positive effects on cognitive function in patients with Obstructive Sleep Apnea (OSA) and narcolepsy, particularly those experiencing Excessive Daytime Sleepiness (EDS). Key findings from the SHARP study, led by Professor Hans Van Dongen, demonstrated improvements in executive function, memory, and processing speed. Presentations included two oral plenary sessions and multiple poster sessions, emphasizing solriamfetol's impact on various cognitive metrics and real-world applications.
Axsome Therapeutics (NASDAQ: AXSM) will present data from its CNS disorder therapies at the American Society of Clinical Psychopharmacology Annual Meeting from May 28-31, 2024, in Miami Beach, Florida. Key presentations include:
1. Post-hoc analyses of Auvelity® demonstrating significant improvements in anhedonic and daily functioning in major depressive disorder (MDD) patients.
2. Data on AXS-05's clinical profile for treating Alzheimer's disease agitation, showcasing promising results from the Phase 2/3 development program.
3. Findings on Solriamfetol's efficacy in enhancing cognitive performance in sleep apnea patients from both preclinical and clinical studies.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will be represented by Chief Executive Officer, Dr. Herriot Tabuteau, at two upcoming investor conferences. The company focuses on developing novel therapies for central nervous system disorders. The presentations will take place at the RBC Capital Markets 2024 Global Healthcare Conference on May 14 and the Bank of America 2024 Healthcare Conference on May 16. Investors can watch the events live on the company's website.
Axsome Therapeutics reported strong financial results for the first quarter of 2024, with total net product revenue of $75.0 million, representing significant year-over-year growth. The company announced positive Phase 3 trial results for AXS-12 in narcolepsy, with other key pipeline programs progressing well. However, the increase in research and development expenses, higher selling, general, and administrative expenses, and a net loss of $68.4 million for the quarter are some challenges highlighted in the financial report.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.